• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

整合原发性肿瘤和脾脏的多模态计算机断层扫描放射组学特征以预测术后辅助经动脉化疗栓塞患者的早期复发

Integration of Multimodal Computed Tomography Radiomic Features of Primary Tumors and the Spleen to Predict Early Recurrence in Patients with Postoperative Adjuvant Transarterial Chemoembolization.

作者信息

Chen Cong, Liu Jian, Gu Zhuxin, Sun Yanjun, Lu Wenwu, Liu Xiaokan, Chen Kang, Ma Tianzhi, Zhao Suming, Zhao Hui

机构信息

Department of Interventional & Vascular Surgery, Affiliated Hospital of Nantong University, Nantong, 226001, People's Republic of China.

Dalian Medical University and Affiliated Hospital of Nantong University, Nantong, 226001, People's Republic of China.

出版信息

J Hepatocell Carcinoma. 2023 Aug 8;10:1295-1308. doi: 10.2147/JHC.S423129. eCollection 2023.

DOI:10.2147/JHC.S423129
PMID:37576612
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10422964/
Abstract

BACKGROUND

Hepatocellular carcinoma (HCC) is one of the most lethal malignancies in the world. Patients with HCC choose postoperative adjuvant transarterial chemoembolization (PA-TACE) after surgical resection to reduce the risk of recurrence. However, many of them have recurrence within a short period.

METHODS

In this retrospective analysis, a total of 173 patients who underwent PA-TACE between September 2016 and March 2020 were recruited. Radiomic features were derived from the arterial and venous phases of each patient. Early recurrence (ER)-related radiomics features of HCC and the spleen were selected to build two rad-scores using the least absolute shrinkage and selection operator (LASSO) Cox regression analysis. Logistic regression was applied to establish the Radiation (Rad)_score by combining the two regions. We constructed a nomogram containing clinical information and dual-region rad-scores, which was evaluated in terms of discrimination, calibration, and clinical usefulness.

RESULTS

All three radiological scores showed good performance for ER prediction. The combined Rad_score performed the best, with an area under the curve (AUC) of 0.853 (95% confidence interval [CI], 0.783-0.908) in the training set and 0.929 (95% CI, 0.789-0.988) in the validation set. Multivariate analysis identified total bilirubin (TBIL) and the combined Rad_score as independent prognostic factors for ER. The nomogram was found to be clinically valuable, as determined by the decision curves (DCA) and clinical impact curves (CIC).

CONCLUSION

A multimodal dual-region radiomics model combining HCC and the spleen is an independent prognostic tool for ER. The combination of dual-region radiomics features and clinicopathological factors has a good clinical application value.

摘要

背景

肝细胞癌(HCC)是全球最致命的恶性肿瘤之一。HCC患者在手术切除后选择术后辅助经动脉化疗栓塞术(PA-TACE)以降低复发风险。然而,其中许多患者在短期内复发。

方法

在这项回顾性分析中,共纳入了2016年9月至2020年3月期间接受PA-TACE的173例患者。从每位患者的动脉期和静脉期提取影像组学特征。选择HCC和脾脏的早期复发(ER)相关影像组学特征,使用最小绝对收缩和选择算子(LASSO)Cox回归分析构建两个影像组学评分。应用逻辑回归通过合并两个区域来建立放射(Rad)评分。我们构建了一个包含临床信息和双区域影像组学评分的列线图,并对其判别能力、校准度和临床实用性进行了评估。

结果

所有三个放射学评分在ER预测方面均表现良好。联合Rad评分表现最佳,在训练集中曲线下面积(AUC)为0.853(95%置信区间[CI],0.783-0.908),在验证集中为0.929(95%CI,0.789-0.988)。多变量分析确定总胆红素(TBIL)和联合Rad评分是ER的独立预后因素。通过决策曲线(DCA)和临床影响曲线(CIC)确定,列线图具有临床价值。

结论

结合HCC和脾脏的多模态双区域影像组学模型是ER的独立预后工具。双区域影像组学特征与临床病理因素的结合具有良好的临床应用价值。

相似文献

1
Integration of Multimodal Computed Tomography Radiomic Features of Primary Tumors and the Spleen to Predict Early Recurrence in Patients with Postoperative Adjuvant Transarterial Chemoembolization.整合原发性肿瘤和脾脏的多模态计算机断层扫描放射组学特征以预测术后辅助经动脉化疗栓塞患者的早期复发
J Hepatocell Carcinoma. 2023 Aug 8;10:1295-1308. doi: 10.2147/JHC.S423129. eCollection 2023.
2
Computed tomography radiomic features and clinical factors predicting the response to first transarterial chemoembolization in intermediate-stage hepatocellular carcinoma.基于 CT 影像组学特征与临床因素预测中期肝细胞癌患者首次经动脉化疗栓塞治疗反应的研究
Hepatobiliary Pancreat Dis Int. 2024 Aug;23(4):361-369. doi: 10.1016/j.hbpd.2023.06.011. Epub 2023 Jul 5.
3
Development of a computed tomography-based radiomics nomogram for prediction of transarterial chemoembolization refractoriness in hepatocellular carcinoma.基于计算机断层扫描的影像组学列线图用于预测肝细胞癌经动脉化疗栓塞难治性的研究进展
World J Gastroenterol. 2021 Jan 14;27(2):189-207. doi: 10.3748/wjg.v27.i2.189.
4
Development of a novel combined nomogram model integrating Rad-score, age and ECOG to predict the survival of patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization.开发一种整合Rad评分、年龄和东部肿瘤协作组(ECOG)评分的新型联合列线图模型,以预测经肝动脉化疗栓塞治疗的肝细胞癌患者的生存率。
J Gastrointest Oncol. 2022 Aug;13(4):1889-1897. doi: 10.21037/jgo-22-548.
5
A Radiomics Signature-Based Nomogram to Predict the Progression-Free Survival of Patients With Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization Plus Radiofrequency Ablation.一种基于放射组学特征的列线图,用于预测经动脉化疗栓塞联合射频消融后肝细胞癌患者的无进展生存期。
Front Mol Biosci. 2021 Aug 31;8:662366. doi: 10.3389/fmolb.2021.662366. eCollection 2021.
6
A radiomics nomogram for predicting transcatheter arterial chemoembolization refractoriness of hepatocellular carcinoma without extrahepatic metastasis or macrovascular invasion.一种用于预测无肝外转移或大血管侵犯的肝细胞癌经动脉化疗栓塞难治性的影像组学列线图。
Abdom Radiol (NY). 2021 Jun;46(6):2839-2849. doi: 10.1007/s00261-020-02884-x. Epub 2021 Jan 2.
7
F-FDG PET/CT-based radiomics nomogram for preoperative prediction of macrotrabecular-massive hepatocellular carcinoma: a two-center study.基于F-FDG PET/CT的影像组学列线图用于术前预测大结节型-巨块型肝细胞癌:一项双中心研究
Abdom Radiol (NY). 2023 Feb;48(2):532-542. doi: 10.1007/s00261-022-03722-y. Epub 2022 Nov 12.
8
A Radiomics Nomogram for Preoperative Prediction of Early Recurrence of Small Hepatocellular Carcinoma After Surgical Resection or Radiofrequency Ablation.一种用于术前预测小肝细胞癌手术切除或射频消融后早期复发的影像组学列线图。
Front Oncol. 2021 Apr 29;11:657039. doi: 10.3389/fonc.2021.657039. eCollection 2021.
9
Prediction of tumor response via a pretreatment MRI radiomics-based nomogram in HCC treated with TACE.基于 MRI 影像组学的Nomogram 模型预测 TACE 治疗 HCC 的肿瘤应答情况。
Eur Radiol. 2021 Oct;31(10):7500-7511. doi: 10.1007/s00330-021-07910-0. Epub 2021 Apr 16.
10
Radiomics Analysis Based on Contrast-Enhanced MRI for Prediction of Therapeutic Response to Transarterial Chemoembolization in Hepatocellular Carcinoma.基于对比增强磁共振成像的放射组学分析预测肝细胞癌经动脉化疗栓塞术的治疗反应
Front Oncol. 2021 Mar 31;11:582788. doi: 10.3389/fonc.2021.582788. eCollection 2021.

引用本文的文献

1
A Clinical-Imaging Nomogram for Predicting Early Recurrence in Patients with Solitary Hepatocellular Carcinoma After Postoperative Adjuvant TACE.一种用于预测孤立性肝细胞癌患者术后辅助性经动脉化疗栓塞术后早期复发的临床影像列线图。
J Hepatocell Carcinoma. 2025 Aug 19;12:1835-1847. doi: 10.2147/JHC.S544127. eCollection 2025.
2
Systemic immune-related spleen radiomics predict progression-free survival in patients with locally advanced cervical cancer underwent definitive chemoradiotherapy.全身免疫相关脾脏放射组学预测行根治性放化疗的局部晚期宫颈癌患者的无进展生存期。
BMC Med Imaging. 2024 Nov 15;24(1):310. doi: 10.1186/s12880-024-01492-1.
3

本文引用的文献

1
Superstable homogeneous iodinated formulation technology: revolutionizing transcatheter arterial chemoembolization.超稳定均匀碘化制剂技术:革新经导管动脉化疗栓塞术
Sci Bull (Beijing). 2020 Oct 30;65(20):1685-1687. doi: 10.1016/j.scib.2020.06.029. Epub 2020 Jun 19.
2
Conversion therapy of intermediate and advanced hepatocellular carcinoma using superstable homogeneous iodinated formulation technology.使用超稳定均匀碘化制剂技术对中晚期肝细胞癌进行转化治疗。
Sci China Life Sci. 2022 Oct;65(10):2114-2117. doi: 10.1007/s11427-022-2142-3. Epub 2022 Aug 26.
3
Prognosis factors of predicting survival in spontaneously ruptured hepatocellular carcinoma.
Artificial intelligence in predicting recurrence after first-line treatment of liver cancer: a systematic review and meta-analysis.
人工智能在预测肝癌一线治疗后复发中的应用:系统评价和荟萃分析。
BMC Med Imaging. 2024 Oct 7;24(1):263. doi: 10.1186/s12880-024-01440-z.
自发性破裂肝细胞癌患者生存预后的预测因素。
Hepatol Int. 2022 Dec;16(6):1330-1338. doi: 10.1007/s12072-022-10403-x. Epub 2022 Aug 25.
4
Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements.肝细胞癌的系统治疗:基于中国共识的多学科专家声明
Liver Cancer. 2022 Jan 4;11(3):192-208. doi: 10.1159/000521596. eCollection 2022 Jun.
5
Development of a prognostic score for recommended transarterial chemoembolization candidates with spontaneous rupture of hepatocellular carcinoma.针对推荐进行经动脉化疗栓塞的肝细胞癌自发性破裂患者的预后评分系统的开发。
J Gastrointest Oncol. 2022 Jun;13(3):1376-1383. doi: 10.21037/jgo-22-531.
6
[Standardization for diagnosis and treatment of hepatocellular carcinoma (2022 edition)].《肝细胞癌诊疗规范(2022年版)》
Zhonghua Gan Zang Bing Za Zhi. 2022 Apr 20;30(4):367-388. doi: 10.3760/cma.j.cn501113-20220413-00193.
7
Progress of targeted and immunotherapy for hepatocellular carcinoma and the application of next-generation sequencing.肝细胞癌靶向治疗与免疫治疗进展及新一代测序技术的应用
Ann Hepatol. 2022 Mar-Apr;27(2):100677. doi: 10.1016/j.aohep.2022.100677. Epub 2022 Jan 28.
8
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.BCLC 策略用于预后预测和治疗推荐:2022 年更新版。
J Hepatol. 2022 Mar;76(3):681-693. doi: 10.1016/j.jhep.2021.11.018. Epub 2021 Nov 19.
9
Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: consensus statement from an international expert panel of International Society of Multidisciplinary Interventional Oncology (ISMIO).肝细胞癌经动脉化疗栓塞术的临床实践:国际多学科介入肿瘤学会(ISMIO)国际专家小组的共识声明
Hepatobiliary Surg Nutr. 2021 Oct;10(5):661-671. doi: 10.21037/hbsn-21-260.
10
[Chinese clinical practice guidelines for transarterial chemoembolization of hepatocellular carcinoma].[肝细胞癌经动脉化疗栓塞术中国临床实践指南]
Zhonghua Nei Ke Za Zhi. 2021 Jul 1;60(7):599-614. doi: 10.3760/cma.j.cn112137-20210425-00991.